Merck & Co Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (119)

Latest Posts

About This Stock More About This Stock
Key FDA Events In June Investors Need To Watch Out For
Article By: Zacks Investment Research
Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
In this article: MRK, VRX, ARRY, GWPH, ALKS, AKAO
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Trump Announces Plan To Reign In Drug Prices And Pharma Stocks Rally
Article By: Zacks Investment Research
Sunday, May 13, 2018 11:37 AM EDT
President Trump unveiled his plan to control US drug prices. Stock prices of the biggest drug companies briefly declined, only to reverse course and ended the day broadly higher. The reason? The plan doesn’t seem to be “taking them on” at all.
In this article: LLY, MRK, AMGN, EXEL, ABBV
Read
Pharma Stock Roundup: Mixed Q1 For MRK, PFE, FDA Nod For Kymriah's 2nd Indication
Article By: Zacks Investment Research
Friday, May 4, 2018 8:15 PM EDT
First-quarter results of pharma bigwigs like Pfizer, Merck and Allergan stole the limelight this week. Other than that, Novartis gained FDA approval for the second indication of its CAR-T therapy, Kymriah.
In this article: AGN, JNJ, MRK, NVS, PFE, UTHR, ABBV
Read
Merck (MRK) Beats On Q1 Earnings, Lags Sales, Raises Outlook
Article By: Zacks Investment Research
Tuesday, May 1, 2018 2:07 PM EDT
Merck & Co., Inc. reported first-quarter 2018 adjusted earnings of $1.05 per share, which beat Zacks' Consensus Estimate of 99 cents by 6.1%. Earnings rose 19.3% year over year attributable to slightly higher sales and lower R&D costs.
In this article: MRK Also: GSK, JNJ, LGND
Read

PARTNER HEADLINES

Latest Tweets for $MRK

No tweets yet!

$MRK

OncoSec Raising Its Profile In Fight Against Cancer
Harry Goldstein 9/7/2017 5:43:14 PM

I appreciate a promising investment that also helps people. Bullish on $ONCS and $MRK.

OncoSec Raising Its Profile In Fight Against Cancer
Alexis Renault 9/6/2017 4:08:15 PM

Thanks for this info, Terry Chrisomalis. Is there any sort of official partnership or cooperation between #OncoSecMedical and #Merck to use ImmunoPulse IL-12 technology in conjunction with #Keytruda? $ONCS $MRK

OncoSec Raising Its Profile In Fight Against Cancer
Dick Kaplan 9/6/2017 4:03:09 PM

Very impressed with the #OncosSec trial results. $ONCS $MRK $BMY

1 to 3 of 3 comments